Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.

Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.

Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.

Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.

Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021

Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.

Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.

Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.

Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.

Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021

Key clinical point: A strict approach toward treat-to-target (T2T) management did not reduce radiographic progression in a daily practice cohort of patients with active rheumatoid arthritis (RA) compared with a relatively lenient approach toward T2T.

Major finding: A T2T approach in a 3-month interval failed to reduce radiographic progression in the same 6-month period with 2 vs 0 visits (change in Sharp-van der Heijde score [Δ] 0.15 units; 95% CI −0.04 to 0.33) and 1 vs 0 visits (Δ 0.08 units; 95% CI −0.06 to 0.22) after T2T.

Study details: This longitudinal analysis of a 2-year prospective observational study cohort included 521 patients with active RA who started or changed conventional synthetic or biologic disease-modifying antirheumatic drugs and underwent treatment intensification according to the T2T approach.

Disclosures: The BIODAM study was supported by an unrestricted grant from AbbVie. Several authors reported receiving research grants, consulting fees, honoraria, or an unrestricted educational grant from various sources, including AbbVie.

Source: Ramiro S et al. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). 2023 (Jan 16). Doi:10.1093/rheumatology/kead021

Key clinical point: Rheumatoid arthritis (RA) is associated with a high risk for end-stage renal disease, with the risk being prominent among relatively young and comorbidity-free individuals and those who consume alcohol.

Major finding: Patients with RA were at a significantly higher risk for end-stage renal disease compared with those without RA (adjusted hazard ratio 2.153; 95% CI 1.948-2.379), particularly among patients who were relatively young (P_interaction < .001), those without comorbidities (P_interaction < .001), and those who consumed alcohol (P_interaction  =  .021).

Study details: This retrospective population-based study included 154,997 patients with RA and 774,985 age- and sex-matched individuals without RA.

Disclosures: This study was supported by grants from the Chonnam National University Hospital Biomedical Research Institute and National Research Foundation of Korea, funded by the Korea Government. The authors declared no conflicts of interest.

Source: Suh SH et al. Rheumatoid arthritis and the risk of end-stage renal disease: A nationwide, population-based study. Front Med (Lausanne). 2023;10:1116489 (Feb 2). Doi: 10.3389/fmed.2023.1116489

Key clinical point: Rheumatoid arthritis (RA) is associated with a high risk for end-stage renal disease, with the risk being prominent among relatively young and comorbidity-free individuals and those who consume alcohol.

Major finding: Patients with RA were at a significantly higher risk for end-stage renal disease compared with those without RA (adjusted hazard ratio 2.153; 95% CI 1.948-2.379), particularly among patients who were relatively young (P_interaction < .001), those without comorbidities (P_interaction < .001), and those who consumed alcohol (P_interaction  =  .021).

Study details: This retrospective population-based study included 154,997 patients with RA and 774,985 age- and sex-matched individuals without RA.

Disclosures: This study was supported by grants from the Chonnam National University Hospital Biomedical Research Institute and National Research Foundation of Korea, funded by the Korea Government. The authors declared no conflicts of interest.

Source: Suh SH et al. Rheumatoid arthritis and the risk of end-stage renal disease: A nationwide, population-based study. Front Med (Lausanne). 2023;10:1116489 (Feb 2). Doi: 10.3389/fmed.2023.1116489

Key clinical point: Rheumatoid arthritis (RA) is associated with a high risk for end-stage renal disease, with the risk being prominent among relatively young and comorbidity-free individuals and those who consume alcohol.

Major finding: Patients with RA were at a significantly higher risk for end-stage renal disease compared with those without RA (adjusted hazard ratio 2.153; 95% CI 1.948-2.379), particularly among patients who were relatively young (P_interaction < .001), those without comorbidities (P_interaction < .001), and those who consumed alcohol (P_interaction  =  .021).

Study details: This retrospective population-based study included 154,997 patients with RA and 774,985 age- and sex-matched individuals without RA.

Disclosures: This study was supported by grants from the Chonnam National University Hospital Biomedical Research Institute and National Research Foundation of Korea, funded by the Korea Government. The authors declared no conflicts of interest.

Source: Suh SH et al. Rheumatoid arthritis and the risk of end-stage renal disease: A nationwide, population-based study. Front Med (Lausanne). 2023;10:1116489 (Feb 2). Doi: 10.3389/fmed.2023.1116489

Key clinical point: Pregnant women with vs without rheumatoid arthritis (RA) and their infants should be closely monitored prenatally and during the year after delivery as they are at a higher risk for rehospitalization within 2 years and more likely to require intensive prenatal or neonatal care.

Major finding: Women with vs without RA required more intensive prenatal care (adjusted relative risk [aRR] 1.46; 95% CI 1.33-1.60) and had a higher risk for postpartum non-pregnancy rehospitalization <2 years after delivery (aRR 1.33; 95% CI 1.13-1.56). Infants of women with vs without RA had a higher risk for neonatal intensive care unit admission (aRR 1.89; 95% CI 1.56-2.30) and rehospitalization <2 years after birth (aRR 1.22; 95% CI 1.01-1.46).

Study details: This population-based retrospective cohort study included pregnant women with (n = 1223) and without (n = 12,293) RA and those with (n = 1354) and without (n = 13,751) systemic lupus erythematosus.

Disclosures: This study was funded by Eunice Kennedy Shriver National Institute of Child Health & Human Development, US National Institutes of Health. The authors did not report conflicts of interest.

Source: Singh N et al. Birth outcomes and re-hospitalizations among pregnant women with rheumatoid arthritis and systemic lupus erythematosus and their offspring. Arthritis Care Res (Hoboken). 2023 (Jan 10). Doi: 10.1002/acr.25087

Key clinical point: Pregnant women with vs without rheumatoid arthritis (RA) and their infants should be closely monitored prenatally and during the year after delivery as they are at a higher risk for rehospitalization within 2 years and more likely to require intensive prenatal or neonatal care.

Major finding: Women with vs without RA required more intensive prenatal care (adjusted relative risk [aRR] 1.46; 95% CI 1.33-1.60) and had a higher risk for postpartum non-pregnancy rehospitalization <2 years after delivery (aRR 1.33; 95% CI 1.13-1.56). Infants of women with vs without RA had a higher risk for neonatal intensive care unit admission (aRR 1.89; 95% CI 1.56-2.30) and rehospitalization <2 years after birth (aRR 1.22; 95% CI 1.01-1.46).

Study details: This population-based retrospective cohort study included pregnant women with (n = 1223) and without (n = 12,293) RA and those with (n = 1354) and without (n = 13,751) systemic lupus erythematosus.

Disclosures: This study was funded by Eunice Kennedy Shriver National Institute of Child Health & Human Development, US National Institutes of Health. The authors did not report conflicts of interest.

Source: Singh N et al. Birth outcomes and re-hospitalizations among pregnant women with rheumatoid arthritis and systemic lupus erythematosus and their offspring. Arthritis Care Res (Hoboken). 2023 (Jan 10). Doi: 10.1002/acr.25087

Key clinical point: Pregnant women with vs without rheumatoid arthritis (RA) and their infants should be closely monitored prenatally and during the year after delivery as they are at a higher risk for rehospitalization within 2 years and more likely to require intensive prenatal or neonatal care.

Major finding: Women with vs without RA required more intensive prenatal care (adjusted relative risk [aRR] 1.46; 95% CI 1.33-1.60) and had a higher risk for postpartum non-pregnancy rehospitalization <2 years after delivery (aRR 1.33; 95% CI 1.13-1.56). Infants of women with vs without RA had a higher risk for neonatal intensive care unit admission (aRR 1.89; 95% CI 1.56-2.30) and rehospitalization <2 years after birth (aRR 1.22; 95% CI 1.01-1.46).

Study details: This population-based retrospective cohort study included pregnant women with (n = 1223) and without (n = 12,293) RA and those with (n = 1354) and without (n = 13,751) systemic lupus erythematosus.

Disclosures: This study was funded by Eunice Kennedy Shriver National Institute of Child Health & Human Development, US National Institutes of Health. The authors did not report conflicts of interest.

Source: Singh N et al. Birth outcomes and re-hospitalizations among pregnant women with rheumatoid arthritis and systemic lupus erythematosus and their offspring. Arthritis Care Res (Hoboken). 2023 (Jan 10). Doi: 10.1002/acr.25087

Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.

Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P  =  .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P  =  .009).

Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039

Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.

Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P  =  .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P  =  .009).

Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039

Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.

Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P  =  .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P  =  .009).

Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039

Key clinical point: The risk for bacterial infections significantly increased with concomitant use of methotrexate and glucocorticoids in patients with rheumatoid arthritis (RA) who were receiving biologic disease-modifying antirheumatic drugs (bDMARD), especially when the doses of concomitant methotrexate and glucocorticoids were ≥8 mg/week and ≥5 mg/day, respectively.

Major finding: Overall, the incidence of bacterial infections was 16.8%, with the highest incidence (25.5%) observed in patients receiving combination therapy with methotrexate (≥8 mg/week) and glucocorticoids (≥5 mg/day). Co-prescription of ≥5 mg/day glucocorticoids with an increasing methotrexate dose (P  =  .013) and ≥8 mg/week methotrexate with an increasing glucocorticoid dose (P  =  .009) significantly increased the risk for bacterial infections.

Study details: This retrospective cohort study included 2837 patients with RA who initiated bDMARD with concomitant conventional synthetic DMARD, methotrexate, or oral glucocorticoids.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Ota R et al. Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study. Br J Clin Pharmacol. 2023 (Feb 8). Doi: 10.1111/bcp.15687

Key clinical point: The risk for bacterial infections significantly increased with concomitant use of methotrexate and glucocorticoids in patients with rheumatoid arthritis (RA) who were receiving biologic disease-modifying antirheumatic drugs (bDMARD), especially when the doses of concomitant methotrexate and glucocorticoids were ≥8 mg/week and ≥5 mg/day, respectively.

Major finding: Overall, the incidence of bacterial infections was 16.8%, with the highest incidence (25.5%) observed in patients receiving combination therapy with methotrexate (≥8 mg/week) and glucocorticoids (≥5 mg/day). Co-prescription of ≥5 mg/day glucocorticoids with an increasing methotrexate dose (P  =  .013) and ≥8 mg/week methotrexate with an increasing glucocorticoid dose (P  =  .009) significantly increased the risk for bacterial infections.

Study details: This retrospective cohort study included 2837 patients with RA who initiated bDMARD with concomitant conventional synthetic DMARD, methotrexate, or oral glucocorticoids.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Ota R et al. Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study. Br J Clin Pharmacol. 2023 (Feb 8). Doi: 10.1111/bcp.15687

Key clinical point: The risk for bacterial infections significantly increased with concomitant use of methotrexate and glucocorticoids in patients with rheumatoid arthritis (RA) who were receiving biologic disease-modifying antirheumatic drugs (bDMARD), especially when the doses of concomitant methotrexate and glucocorticoids were ≥8 mg/week and ≥5 mg/day, respectively.

Major finding: Overall, the incidence of bacterial infections was 16.8%, with the highest incidence (25.5%) observed in patients receiving combination therapy with methotrexate (≥8 mg/week) and glucocorticoids (≥5 mg/day). Co-prescription of ≥5 mg/day glucocorticoids with an increasing methotrexate dose (P  =  .013) and ≥8 mg/week methotrexate with an increasing glucocorticoid dose (P  =  .009) significantly increased the risk for bacterial infections.

Study details: This retrospective cohort study included 2837 patients with RA who initiated bDMARD with concomitant conventional synthetic DMARD, methotrexate, or oral glucocorticoids.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Ota R et al. Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study. Br J Clin Pharmacol. 2023 (Feb 8). Doi: 10.1111/bcp.15687

Key clinical point: Long-term sarilumab with or without background conventional synthetic disease-modifying antirheumatic drugs (csDMARD) was safe and provided sustained or improved clinical efficacy along with no new safety signals in patients with active rheumatoid arthritis (RA).

Major finding: Among patients receiving sarilumab monotherapy and sarilumab+csDMARD therapy, 88.3% and 92.1% of patients experienced ≥1 treatment-emergent adverse event (TEAE) and TEAE-related death rates were 1.8% and 2.1%, respectively; no new safety signals were identified. The proportion of patients achieving Clinical Disease Activity Index remission was maintained for all treatment groups.

Study details: This study evaluated 2021 and 320 patients with active RA from two open-label extension (OLE) trials (EXTEND and MONARCH, respectively) who had inadequate response, intolerance, or failure with treatment with methotrexate or tumor necrosis factor inhibitors and received sarilumab with or without csDMARD.

Disclosures: This study was supported by Sanofi. The OLE studies were sponsored by Sanofi and Regeneron. Four authors declared being employees of or holding shares or stock options in Sanofi. Several authors reported ties with Sanofi, Regeneron, and other sources.

Source: Burmester GR et al. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2023 (Feb 2). Doi: 10.1093/rheumatology/kead062

Key clinical point: Long-term sarilumab with or without background conventional synthetic disease-modifying antirheumatic drugs (csDMARD) was safe and provided sustained or improved clinical efficacy along with no new safety signals in patients with active rheumatoid arthritis (RA).

Major finding: Among patients receiving sarilumab monotherapy and sarilumab+csDMARD therapy, 88.3% and 92.1% of patients experienced ≥1 treatment-emergent adverse event (TEAE) and TEAE-related death rates were 1.8% and 2.1%, respectively; no new safety signals were identified. The proportion of patients achieving Clinical Disease Activity Index remission was maintained for all treatment groups.

Study details: This study evaluated 2021 and 320 patients with active RA from two open-label extension (OLE) trials (EXTEND and MONARCH, respectively) who had inadequate response, intolerance, or failure with treatment with methotrexate or tumor necrosis factor inhibitors and received sarilumab with or without csDMARD.

Disclosures: This study was supported by Sanofi. The OLE studies were sponsored by Sanofi and Regeneron. Four authors declared being employees of or holding shares or stock options in Sanofi. Several authors reported ties with Sanofi, Regeneron, and other sources.

Source: Burmester GR et al. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2023 (Feb 2). Doi: 10.1093/rheumatology/kead062

Key clinical point: Long-term sarilumab with or without background conventional synthetic disease-modifying antirheumatic drugs (csDMARD) was safe and provided sustained or improved clinical efficacy along with no new safety signals in patients with active rheumatoid arthritis (RA).

Major finding: Among patients receiving sarilumab monotherapy and sarilumab+csDMARD therapy, 88.3% and 92.1% of patients experienced ≥1 treatment-emergent adverse event (TEAE) and TEAE-related death rates were 1.8% and 2.1%, respectively; no new safety signals were identified. The proportion of patients achieving Clinical Disease Activity Index remission was maintained for all treatment groups.

Study details: This study evaluated 2021 and 320 patients with active RA from two open-label extension (OLE) trials (EXTEND and MONARCH, respectively) who had inadequate response, intolerance, or failure with treatment with methotrexate or tumor necrosis factor inhibitors and received sarilumab with or without csDMARD.

Disclosures: This study was supported by Sanofi. The OLE studies were sponsored by Sanofi and Regeneron. Four authors declared being employees of or holding shares or stock options in Sanofi. Several authors reported ties with Sanofi, Regeneron, and other sources.

Source: Burmester GR et al. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2023 (Feb 2). Doi: 10.1093/rheumatology/kead062

Key clinical point: Migraine history was associated with poor sleep quality in premenopausal women, but not in perimenopausal women.

Major finding: A significant association was observed between migraine history and poor sleep quality in premenopausal women (odds ratio [OR] 1.4; 95% CI 1.01-2.04; P  =  .044) but not in perimenopausal women (OR 1.14; 95% CI 0.80-1.64; P  =  .46).

Study details: The data come from a cross-sectional analysis of 2067 women (premenopausal n = 962; perimenopausal n = 1105) from the Data Registry on the Experiences of Aging, Menopause, and Sexuality, of which 594 (28.7%) had a migraine history.

Disclosures: This study did not receive any funding. Some authors declared being consultants for or receiving past funding, consulting fees, grant support, or honoraria from various organizations.

Source: Faubion SS et al. Migraine and sleep quality: Does the association change in midlife women? Menopause. 2023 (Jan 31). Doi: 10.1097/GME.0000000000002149

Key clinical point: Migraine history was associated with poor sleep quality in premenopausal women, but not in perimenopausal women.

Major finding: A significant association was observed between migraine history and poor sleep quality in premenopausal women (odds ratio [OR] 1.4; 95% CI 1.01-2.04; P  =  .044) but not in perimenopausal women (OR 1.14; 95% CI 0.80-1.64; P  =  .46).

Study details: The data come from a cross-sectional analysis of 2067 women (premenopausal n = 962; perimenopausal n = 1105) from the Data Registry on the Experiences of Aging, Menopause, and Sexuality, of which 594 (28.7%) had a migraine history.

Disclosures: This study did not receive any funding. Some authors declared being consultants for or receiving past funding, consulting fees, grant support, or honoraria from various organizations.

Source: Faubion SS et al. Migraine and sleep quality: Does the association change in midlife women? Menopause. 2023 (Jan 31). Doi: 10.1097/GME.0000000000002149

Key clinical point: Migraine history was associated with poor sleep quality in premenopausal women, but not in perimenopausal women.

Major finding: A significant association was observed between migraine history and poor sleep quality in premenopausal women (odds ratio [OR] 1.4; 95% CI 1.01-2.04; P  =  .044) but not in perimenopausal women (OR 1.14; 95% CI 0.80-1.64; P  =  .46).

Study details: The data come from a cross-sectional analysis of 2067 women (premenopausal n = 962; perimenopausal n = 1105) from the Data Registry on the Experiences of Aging, Menopause, and Sexuality, of which 594 (28.7%) had a migraine history.

Disclosures: This study did not receive any funding. Some authors declared being consultants for or receiving past funding, consulting fees, grant support, or honoraria from various organizations.

Source: Faubion SS et al. Migraine and sleep quality: Does the association change in midlife women? Menopause. 2023 (Jan 31). Doi: 10.1097/GME.0000000000002149

Key clinical point: Migraine may be associated with an increased risk for any stroke and ischemic stroke in middle-aged and elderly populations.

Major finding: Findings suggested an association between migraine and risk for any stroke (adjusted hazard ratio [aHR] 1.44; P  =  .076) and ischemic stroke (aHR 1.50; P  =  .067), but without statistical significance.

Study details: This ongoing prospective population-based cohort study included 6925 stroke-free participants, of which 1030 participants had a lifetime history of migraine and 195 participants developed incident stroke.

Disclosures: This study received funding from Erasmus Medical Center, Erasmus University, Netherlands, and other sources. AMVD Brink declared receiving support from the Dutch Research Council and research grants or consulting fees from AbbVie/Allergan and other sources.

Source: Acarsoy C et al. Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study. Cephalalgia. 2023;43(1):3331024221132008 (Jan 9). Doi: 10.1177/03331024221132008

Key clinical point: Migraine may be associated with an increased risk for any stroke and ischemic stroke in middle-aged and elderly populations.

Major finding: Findings suggested an association between migraine and risk for any stroke (adjusted hazard ratio [aHR] 1.44; P  =  .076) and ischemic stroke (aHR 1.50; P  =  .067), but without statistical significance.

Study details: This ongoing prospective population-based cohort study included 6925 stroke-free participants, of which 1030 participants had a lifetime history of migraine and 195 participants developed incident stroke.

Disclosures: This study received funding from Erasmus Medical Center, Erasmus University, Netherlands, and other sources. AMVD Brink declared receiving support from the Dutch Research Council and research grants or consulting fees from AbbVie/Allergan and other sources.

Source: Acarsoy C et al. Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study. Cephalalgia. 2023;43(1):3331024221132008 (Jan 9). Doi: 10.1177/03331024221132008

Key clinical point: Migraine may be associated with an increased risk for any stroke and ischemic stroke in middle-aged and elderly populations.

Major finding: Findings suggested an association between migraine and risk for any stroke (adjusted hazard ratio [aHR] 1.44; P  =  .076) and ischemic stroke (aHR 1.50; P  =  .067), but without statistical significance.

Study details: This ongoing prospective population-based cohort study included 6925 stroke-free participants, of which 1030 participants had a lifetime history of migraine and 195 participants developed incident stroke.

Disclosures: This study received funding from Erasmus Medical Center, Erasmus University, Netherlands, and other sources. AMVD Brink declared receiving support from the Dutch Research Council and research grants or consulting fees from AbbVie/Allergan and other sources.

Source: Acarsoy C et al. Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study. Cephalalgia. 2023;43(1):3331024221132008 (Jan 9). Doi: 10.1177/03331024221132008

Key clinical point: Acupuncture showed a similar preventive treatment effect to fremanezumab in patients with episodic migraine; however, acupuncture was associated with lower adverse event rates.

Major finding: Compared with acupuncture, monthly and single-dose fremanezumab showed similar decrease in monthly migraine days (P  =  .473 and P  =  .214, respectively) and 50% responder rate (P  =  .17 and P  =  .109, respectively).  The adverse event risk was lower with acupuncture (25%) vs monthly and single-dose fremanezumab (both 66%).

Study details: This study evaluated 302 patients with episodic migraine from an acupuncture trial (acupuncture n = 145; sham acupuncture n = 81; waiting-list control n = 76) and 875 patients with episodic migraine from the fremanezumab trial (monthly fremanezumab n = 290; single-dose fremanezumab n = 291; placebo n = 294).

Disclosures: This study did not declare a funding source. The authors declared no conflicts of interest.

Source: Zheng H et al. Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine. Curr Med Res Opin. 2023 (Feb 8). Doi: 10.1080/03007995.2023.2174746

Key clinical point: Acupuncture showed a similar preventive treatment effect to fremanezumab in patients with episodic migraine; however, acupuncture was associated with lower adverse event rates.

Major finding: Compared with acupuncture, monthly and single-dose fremanezumab showed similar decrease in monthly migraine days (P  =  .473 and P  =  .214, respectively) and 50% responder rate (P  =  .17 and P  =  .109, respectively).  The adverse event risk was lower with acupuncture (25%) vs monthly and single-dose fremanezumab (both 66%).

Study details: This study evaluated 302 patients with episodic migraine from an acupuncture trial (acupuncture n = 145; sham acupuncture n = 81; waiting-list control n = 76) and 875 patients with episodic migraine from the fremanezumab trial (monthly fremanezumab n = 290; single-dose fremanezumab n = 291; placebo n = 294).

Disclosures: This study did not declare a funding source. The authors declared no conflicts of interest.

Source: Zheng H et al. Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine. Curr Med Res Opin. 2023 (Feb 8). Doi: 10.1080/03007995.2023.2174746

Key clinical point: Acupuncture showed a similar preventive treatment effect to fremanezumab in patients with episodic migraine; however, acupuncture was associated with lower adverse event rates.

Major finding: Compared with acupuncture, monthly and single-dose fremanezumab showed similar decrease in monthly migraine days (P  =  .473 and P  =  .214, respectively) and 50% responder rate (P  =  .17 and P  =  .109, respectively).  The adverse event risk was lower with acupuncture (25%) vs monthly and single-dose fremanezumab (both 66%).

Study details: This study evaluated 302 patients with episodic migraine from an acupuncture trial (acupuncture n = 145; sham acupuncture n = 81; waiting-list control n = 76) and 875 patients with episodic migraine from the fremanezumab trial (monthly fremanezumab n = 290; single-dose fremanezumab n = 291; placebo n = 294).

Disclosures: This study did not declare a funding source. The authors declared no conflicts of interest.

Source: Zheng H et al. Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine. Curr Med Res Opin. 2023 (Feb 8). Doi: 10.1080/03007995.2023.2174746

Key clinical point: Patients with difficult-to-treat chronic migraine and insufficient treatment response after the first 2 cycles of onabotulinumtoxinA showed improvements in migraine-related outcomes after switching to anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs).

Major finding: At 9 months, a higher proportion of patients achieved a ≥50% response rate (65.0% vs 22.4%) and reported a greater reduction in monthly headache days (change from baseline −12.0 vs −5.0 days) with anti-CGRP mAbs vs onabotulinumtoxinA treatment. No serious adverse events were reported. Treatment discontinuation due to adverse events was reported by 2 patients.

Study details: This retrospective analysis included 78 patients with difficult-to-treat chronic migraine with or without medication overuse and ≥2 migraine preventive treatment failures who discontinued onabotulinumtoxinA and switched to anti-CGRP mAbs.

Disclosures: This study did not receive any specific funding. Three authors declared receiving personal fees or grants or serving on a scientific advisory board and as a founding scientist for various sources.

Source: Iannone LF et al. Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs. 2023;37(2):189-202 (Jan 19).  Doi: 10.1007/s40263-022-00983-5

Key clinical point: Patients with difficult-to-treat chronic migraine and insufficient treatment response after the first 2 cycles of onabotulinumtoxinA showed improvements in migraine-related outcomes after switching to anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs).

Major finding: At 9 months, a higher proportion of patients achieved a ≥50% response rate (65.0% vs 22.4%) and reported a greater reduction in monthly headache days (change from baseline −12.0 vs −5.0 days) with anti-CGRP mAbs vs onabotulinumtoxinA treatment. No serious adverse events were reported. Treatment discontinuation due to adverse events was reported by 2 patients.

Study details: This retrospective analysis included 78 patients with difficult-to-treat chronic migraine with or without medication overuse and ≥2 migraine preventive treatment failures who discontinued onabotulinumtoxinA and switched to anti-CGRP mAbs.

Disclosures: This study did not receive any specific funding. Three authors declared receiving personal fees or grants or serving on a scientific advisory board and as a founding scientist for various sources.

Source: Iannone LF et al. Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs. 2023;37(2):189-202 (Jan 19).  Doi: 10.1007/s40263-022-00983-5

Key clinical point: Patients with difficult-to-treat chronic migraine and insufficient treatment response after the first 2 cycles of onabotulinumtoxinA showed improvements in migraine-related outcomes after switching to anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs).

Major finding: At 9 months, a higher proportion of patients achieved a ≥50% response rate (65.0% vs 22.4%) and reported a greater reduction in monthly headache days (change from baseline −12.0 vs −5.0 days) with anti-CGRP mAbs vs onabotulinumtoxinA treatment. No serious adverse events were reported. Treatment discontinuation due to adverse events was reported by 2 patients.

Study details: This retrospective analysis included 78 patients with difficult-to-treat chronic migraine with or without medication overuse and ≥2 migraine preventive treatment failures who discontinued onabotulinumtoxinA and switched to anti-CGRP mAbs.

Disclosures: This study did not receive any specific funding. Three authors declared receiving personal fees or grants or serving on a scientific advisory board and as a founding scientist for various sources.

Source: Iannone LF et al. Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs. 2023;37(2):189-202 (Jan 19).  Doi: 10.1007/s40263-022-00983-5